Lu Xiangyi’s centrifuge has established cooperative relationships with major pharmaceutical companies, helping them undergo transformation and achieve development.

　　Recently, Lu Xiangyi's 8 units L800R Ultra-Large Refrigerated Centrifuge Purchased by a well-known pharmaceutical company, the company’s head, Lu Shan, performed on-site installation and commissioning of the centrifuge for the customer. The L800R ultra-large-capacity refrigerated centrifuge is widely used in central blood banks, pharmaceutical manufacturing, bioengineering, and other fields. It features a high sample-processing capacity and is equipped with a PLC control system that generates unchangeable PDF printouts, stores centrifugation operating parameter data, supports three-level password management, and includes multiple other functions such as electronic signatures.

　　Recently (as reported by YaoXieZhiSheng), Sanofi, Cansino Biologics, Roche, and Innovent Biologics have all announced collaboration deals, creating a powerful alliance that’s shaking up the market!

　　 Sanofi “joins hands” with Conning Jie to position itself in the breast cancer market.

　　Sanofi and Cansino Biologics announced that the two companies have signed an agreement to establish a strategic partnership: Together, they will advance clinical trials of KN026 in combination with Taxotere (docetaxel) for HER2-positive breast cancer patients. KN026 is a bispecific anti-HER2 antibody that can simultaneously bind to two non-overlapping epitopes on HER2, thereby blocking HER2 signaling through a dual mechanism. It is hypothesized that this leads to HER2 aggregation on the cell surface followed by internalization. Early clinical trials have shown that KN026 demonstrates promising preliminary efficacy and excellent safety profile in advanced breast cancer patients who have failed multiple prior treatment regimens, laying a solid foundation for the development of subsequent combination therapies in first-line settings.

　　 Xinda Biologics Completes Several Large-Scale Collaborations

　　On the same day, Innovent Biologics announced a strategic R&D collaboration with Roche Group, covering multiple tumor cell therapies and bispecific antibodies. The collaboration between the two companies will focus on the research, clinical development, and commercialization of several bispecific antibodies and cell therapy products, which will be directly used in the treatment of hematological malignancies and solid tumors.

　　Meanwhile, several pharmaceutical companies have recently stepped up their efforts to develop innovative drugs (according to a report by Information Times). ST Baihua has raised nearly 430 million yuan, which will be used for R&D and industrialization projects under the MAH system, as well as for the development of small-molecule innovative drugs, peptide-based innovative drugs, and PDC drugs. Aidi Pharmaceutical will use the funds raised this time for innovative drug R&D, the purchase of a building for its R&D technology center, the R&D and production of active pharmaceutical ingredients, and the construction of supporting facilities.

　　Recently, Huasen Pharmaceutical also stated on an interactive platform that the company has already taken several steps in the innovative drug sector, including recruiting a chief scientific officer, establishing an innovative drug business unit, building an innovative drug laboratory, and assembling a team of innovative drug talent. These initiatives have either been partially completed or are currently underway, and specific subsequent projects will be advanced in an orderly manner according to plan.

　　In addition, several pharmaceutical companies—including Kolon Pharmaceutical, Guangshengtang, and HealthCare—have all announced adjustments to their organizational structures, signaling their commitment to developing innovative drugs. Renowned economist Song Qinghui told reporters that in recent years, the reason major pharmaceutical companies have stepped up their efforts in innovating drug development is mainly due to factors such as the shrinking profit margins for generic drugs and strong government support, which are compelling pharmaceutical firms to shift toward and invest in innovative drugs. In his view, R&D of innovative drugs has become an essential path for leading pharmaceutical companies.

　　The development of pharmaceutical companies is inseparable from research and development, manufacturing, market access, and promotion. This pharmaceutical industry chain, which took shape as early as the last century, requires Chinese pharmaceutical companies to become globally competitive by significantly increasing R&D investment, adopting robust R&D strategies, achieving remarkable R&D results, and ensuring stable and reliable product quality. All these advancements, in turn, depend on the steady supply of basic instruments and equipment that meet GMP standards.

　　The L800R ultra-large-capacity refrigerated centrifuge is a product specifically developed and manufactured for customers with high-volume requirements. Here are its key technical specifications:

　　● Ultra-large-capacity data storage and fault-log information enable easy tracking of operational history data. Relevant data can be exported and printed. The capacity reaches up to 2400 ml × 6, with a single-sample processing volume of up to 14,400 ml.

　　● Equipped with a 7-inch large-screen, high-definition true-color TFT touch screen for easy operation and intuitive display. Setting parameters and real-time operating parameters can be displayed on the same screen.

　　● Equipped with a high-performance compressor unit imported from abroad and using the fluorine-free refrigerant R404a, which meets environmental protection requirements.

　　● Equipped with a dedicated rotor system for various blood banks, it can centrifuge commonly used triple-bag and quadruple-bag collections in blood banks.

　　● Equipped with rotor identification functionality, an electronic door lock, and multiple protection features—including unbalance detection, self-locking door cover, overspeed protection, and overtemperature protection—to ensure the safe operation of the instrument.

　　●Optional imported PC material available; the centrifuge tubes are transparent and easy to view, extending their service life and allowing for high-pressure sterilization.

　　● A powerful control system enables the recall of segmented, stepwise centrifugation presets and features tiered password management, ensuring safe and reliable instrument operation and facilitating precise management.

　　● Uses an integral sealing ring made of food-grade silicone rubber, compliant with GMP certification. The centrifuge has obtained U.S. FDA certification.

　　*An optional PLC control system can be configured to enable PDF export and printing functionality.

　　Technical Parameters

　　Shanghai Luxiangyi Centrifuge The Instrument Co., Ltd. is a specialized manufacturer of centrifuges, located at No. 9, Lane 4309, Hulan Road, Pudong New Area, Shanghai. The company is renowned for its long-standing manufacturing history, strong technical expertise, sophisticated production equipment, comprehensive testing facilities, reliable product quality, stable performance, and complete range of specifications. Its products are also celebrated for their exquisite design, innovative styling, and superior craftsmanship. Li Guimei, the head of Luxiangyi, felt deeply gratified as she watched her customers give her a thumbs-up in appreciation. Over the years, while focusing on its own development, Shanghai Luxiangyi has never forgotten to give back to society, continuously striving to provide Chinese pharmaceutical companies with centrifuge products that boast outstanding performance and consistently reliable quality.